Clinical characteristics | Baseline evaluation | First clinical re-evaluation Median 113 days from baseline n = 45 | Second clinical re-evaluation Median 238 days from baseline n = 21 | ||
---|---|---|---|---|---|
NSBB N = 65 | On NSBB n = 34 | Not on NSBB n = 9 | On NSBB n = 18 | Not on NSBB n = 3 | |
Mean arterial pressure, mmHg | 82 (76–93) | 89 (75–96) | 79 (73–84) | 85 (79–96) | 87 (69–95) |
MELD | 16 (14–19) | **15 (12–19) | **23 (17–27) | 14 (12–17) | 14 (11–21) |
Creatinine (mg/dL) | 1.1 (0.8–1.4) | *1 (0.8–1.3) | *1.8 (1–2.2) | 0.9 (0.7–1.3) | 0.8 (0.7–1.5) |
Child Pugh Score | 10 (9–11) | 10 (8–11) | 11 (10–12) | 9 (8–10) | 8 (7–12) |
NSBB at baseline | |||||
Propranolol | 36 (56%) | **15 (45%) | **9 (100%) | 7 (35%) | 2 (67%) |
Nadolol | 19 (29%) | 12 (35%) | None | 9 (53%) | None |
Carvedilol | 10 (15%) | 7 (20%) | None | 2 (12%) | 1 (33%) |
Clinical events occurring after the specified evaluation | |||||
Acute kidney injury | 14 (21%) | 3 (9%) | None | **None | **1 (5%) |
Gastrointestinal bleedinga | None | None | None | None | None |
Spontaneous bacterial peritonitis | 4 (6%) | None | None | 1 (5%) | None |
Liver transplant | 1 (2%) | 6 (18%) | 1 (11%) | None | None |
Mortality | 4 (8%) | *1 (3%) | *2 (22%) | 1 (5%) | None |
Lost to follow up | None | None | None | 2 (12%) | 1 (13%) |